{
    "root": "8cc23541-0457-4fc2-8098-4cdf8f5a0d1a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "leflunomide",
    "value": "20241030",
    "ingredients": [
        {
            "name": "LEFLUNOMIDE",
            "code": "G162GK9U4W"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "Leflunomide tablets, USP are indicated for the treatment of adults with active rheumatoid arthritis (RA).",
    "contraindications": "Loading dosage for patients at low risk for leflunomide -associated hepatotoxicity and leflunomide -associated myelosuppression: 100 mg daily for 3 days. ( 2.1 ) Maintenance dosage: 20 mg daily. ( 2.1 ) Maximum recommended daily dosage: 20 mg once daily. ( 2.1) If 20 mg once daily is not tolerated, may decrease dosage to 10 mg once daily. ( 2.1 ) Screen patients for active and latent tuberculosis, pregnancy test (females), blood pressure, and laboratory tests before starting leflunomide tablets . ( 2.2 )",
    "warningsAndPrecautions": "Leflunomide Tablets, USP\n                  10 mg - White, round bi-convex tablet debossed with \"HP 43\" on one side and plain on the other.\n                  NDC: 72162-2409-3: 30 Tablets in a BOTTLE\n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Leflunomide tablets are contraindicated in:\n                  •Pregnant women.  Leflunomide may cause fetal harm.  If a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see Warnings and Precautions (5.1and 5.3) and Use in Specific Populations (8.1)].\n                  •Patients with severe hepatic impairment [see Warnings and Precautions (5.2)].\n                  •Patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. Known reactions include anaphylaxis [see Adverse Reactions (6.1)].\n                  •Patients being treated with teriflunomide [see Drug Interactions (7)]."
}